Showing 1931-1940 of 3223 results for "".
- Alpine and Shamir Extend Strategic Partnership Into Esports Worldhttps://modernod.com/news/alpine-and-shamir-extend-strategic-partnership-into-esports-world/2480654/Shamir has announced a multi-year extension to its partnership with Alpine F1 Team, becoming the optical performance partner of Alpine Esports Team. Shamir will provide ophthalmic assessments and improvement of gaming performance, and endurance through cutting edge lenses and
- Elios Reports 8-Year Results of its Excimer Laser Trabeculostomy Procedure Combined With Cataract Surgeryhttps://modernod.com/news/elios-reports-8-year-results-of-its-excimer-laser-trabeculostomy-procedure-combined-with-cataract-surgery/2480650/Elios Vision announced 8-year follow up results of its Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery. According to Elios, key finding of the study include: 161 eyes of 128 patients with glaucoma or ocular hypertension and cataract rec
- FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmoshttps://modernod.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/FCI Ophthalmics announced <
- Regenxbio Presents Positive Interim Data From Phase 2 ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-presents-positive-interim-data-from-phase-3-altitude-trial-of-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/2480639/Regenxbio announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogene
- Alimera Sciences Announces Launch of Iluvien for Uveitis in Spainhttps://modernod.com/news/alimera-sciences-announces-launch-of-iluvien-for-uveitis-in-spain/2480619/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch Iluvien for noninfectious posterior uveitis in Spain, through its distribution partner, Brill Pharma (Brill). Brill has received a positive resolution fo
- Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Modelhttps://modernod.com/news/aldeyra-therapeutics-announces-publication-of-phase-2-clinical-trial-of-reproxalap-in-allergen-chamber-model/2480608/Aldeyra Therapeutics announced that results from the randomized, double-masked, vehicle-controlled, crossover phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an
- Allotex Announces 3-Year Results of Allogeneic Inlays for the Treatment of Hyperopia and Presbyopiahttps://modernod.com/news/allotex-announces-3-year-results-of-allogeneic-inlays-for-the-treatment-of-hyperopia-and-presbyopia/2480575/Allotex, the maker of
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell
- Aldeyra Therapeutics Announces Positive Topline Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-data-from-phase-2-dry-eye-chamber-clinical-trial-of-reproxalap-for-dry-eye-disease/2480557/Aldeyra Therapeutics announced positive topline data from a phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25%, an investigational new drug, versus Xiidra (lifitegrast ophthalmic solution 5%) in patients with dry ey
- Alcon Completes Acquisition of Ivantis, Bringing Hydrus Microstent into Its Global Surgical Portfoliohttps://modernod.com/news/alcon-completes-acquisition-of-ivantis-bringing-hydrus-microstent-into-its-global-surgical-portfolio/2480555/Alcon announced the closing of its previously announced acquisition of Ivantis, developer of the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surge